Pyrazoles Concept

subject area of

• Lactobacillus reuteriingestion and IK_Cachannel blockade have similar effects on rat colon motility and myenteric neurones  Academic Article
• A Methanol Intoxication Outbreak From Recreational Ingestion of Fracking Fluid  Academic Article
• A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177  Academic Article
• A Survey of the Use of Empiric Novel Anticoagulants During Investigation of Stroke  Academic Article
• A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score  Academic Article
• A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer  Academic Article
• A vortex-assisted MSPD method for the extraction of pesticide residues from fish liver and crab hepatopancreas with determination by GC–MS  Academic Article
• Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial  Academic Article
• Acute management of bleeding in patients on novel oral anticoagulants  Academic Article
• Acute pain after total hip arthroplasty does not predict the development of chronic postsurgical pain 6 months later  Academic Article
• Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study  Academic Article
• Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable b-cell neoplasms: a report of two pilot clinical trials and laboratory investigations  Academic Article
• Advantages and limitations of the new anticoagulants  Academic Article
• An anti-inflammatory drug (BW755C) inhibits airway hyperresponsiveness induced by ozone in dogs  Academic Article
• An assay to measure levels of factor Xa inhibitors in blood and plasma  Academic Article
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors  Academic Article
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity  Academic Article
• Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis  Academic Article
• Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation  Academic Article
• Anomalous ABO Grouping Due to a New Serum Factor Reactive with a Reagent Coloring Material  Academic Article
• Anticoagulation for Mechanical Heart Valves  Academic Article
• Apixaban for Extended Treatment of Venous Thromboembolism  Academic Article
• Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review  Academic Article
• Apixaban in Acute Coronary Syndromes  Academic Article
• Apixaban in Patients with Atrial Fibrillation  Academic Article
• Apixaban to Prevent Venous Thromboembolism in Patients with Cancer  Academic Article
• Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement  Academic Article
• Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients  Academic Article
• Apixaban versus Enoxaparin in Medically Ill Patients  Academic Article
• Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial  Academic Article
• Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial  Academic Article
• Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome  Academic Article
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Academic Article
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Academic Article
• Appropriate Apixaban Dosing  Academic Article
• Aryl Hydrocarbon Receptor-Dependent Retention of Nuclear HuR Suppresses Cigarette Smoke-Induced Cyclooxygenase-2 Expression Independent of DNA-Binding  Academic Article
• Bacteroides fragilis polysaccharide A is necessary and sufficient for acute activation of intestinal sensory neurons  Academic Article
• Beyond Unfractionated Heparin and Warfarin  Academic Article
• Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin  Academic Article
• Bleeding and antidotes in new oral anticoagulants  Academic Article
• Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience  Academic Article
• Bleeding with direct oral anticoagulants vs warfarin: clinical experience  Academic Article
• Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment  Academic Article
• Cannabinoids Reveal Separate Controls for Whisking Amplitude and Timing in Rats  Academic Article
• Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study  Academic Article
• Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial  Academic Article
• Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials  Academic Article
• Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials  Academic Article
• Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• Clinical implications of reversal agents for direct oral anticoagulants  Academic Article
• Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin  Academic Article
• Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications  Academic Article
• Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure  Academic Article
• Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development  Academic Article
• Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis  Academic Article
• Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study  Academic Article
• Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?  Academic Article
• Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents  Academic Article
• Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)  Academic Article
• Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer  Academic Article
• Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia  Academic Article
• Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies  Academic Article
• Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.  Academic Article
• Direct oral anticoagulants: evidence and unresolved issues  Academic Article
• Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial  Academic Article
• Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy  Academic Article
• Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect  Academic Article
• Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty  Academic Article
• Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study  Academic Article
• Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis  Academic Article
• Effect of nafazatrom on platelet function and release: Relationship to symptomatic episodes in patients with peripheral vascular disease  Academic Article
• Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction  Academic Article
• Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial  Academic Article
• Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial  Academic Article
• Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP)  Academic Article
• Energy-stress-mediated AMPK activation inhibits ferroptosis  Academic Article
• Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials  Academic Article
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Academic Article
• Extended treatment of venous thromboembolism.  Academic Article
• Factor Xa and thrombin as targets for new oral anticoagulants  Academic Article
• Functional characterization of estrogen receptor subtypes, ERα and ERβ, mediating vitellogenin production in the liver of rainbow trout  Academic Article
• Gabapentin Decreases Morphine Consumption and Improves Functional Recovery following Total Knee Arthroplasty  Academic Article
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Academic Article
• Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy  Academic Article
• High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells  Academic Article
• How I treat target-specific oral anticoagulant–associated bleeding  Academic Article
• Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study  Academic Article
• Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties  Academic Article
• Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET  Academic Article
• Immunological studies with different classes of mutants affected at the adenosine kinase locus in CHO cells  Academic Article
• In AF, apixaban reduced stroke or systemic embolism compared with warfarin, regardless of patient age  Academic Article
• In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival  Academic Article
• In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding  Academic Article
• Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis  Academic Article
• Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation  Academic Article
• Inhibition of arterial thrombosis and platelet function by nafazatrom  Academic Article
• International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants  Academic Article
• Involvement of adenosine kinase in the phosphorylation of formycin B in CHO cells  Academic Article
• Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells  Academic Article
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Academic Article
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Academic Article
• Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation  Academic Article
• Laboratory measurement of the direct oral anticoagulants  Academic Article
• Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia  Academic Article
• Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES  Academic Article
• Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels  Academic Article
• Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study  Academic Article
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Academic Article
• Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS ₂ and CHA ₂ DS ₂ -VASc Scores in Patients With Atrial Fibrillation  Academic Article
• Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation  Academic Article
• Monitoring and reversal of direct oral anticoagulants  Academic Article
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Academic Article
• New Anticoagulants for Atrial Fibrillation  Academic Article
• New Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• New Anticoagulants for the Prevention of Thromboembolism  Academic Article
• New Antithrombotic Drugs: Potential for Use in Oncology  Academic Article
• New anticoagulants in atrial fibrillation management  Conference Paper
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Academic Article
• New oral anticoagulants and oculoplastic surgery  Academic Article
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Academic Article
• New oral anticoagulants in elderly patients  Academic Article
• New oral anticoagulants: not quite there yet  Academic Article
• New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses  Academic Article
• Novel Oral Anticoagulants: A Focused Review for Stroke Physicians  Academic Article
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism  Academic Article
• Novel oral anticoagulants in gastroenterology practice  Academic Article
• Novel oral anticoagulants in secondary prevention of stroke  Academic Article
• Optimal Prescription of the Lower Dose of Apixaban  Academic Article
• Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants  Academic Article
• Oral Apixaban for the Treatment of Acute Venous Thromboembolism  Academic Article
• Oral Direct Factor Xa Inhibitors  Academic Article
• Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease  Academic Article
• Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation  Academic Article
• Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation  Academic Article
• Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation  Academic Article
• Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial  Academic Article
• Overview of the New Oral Anticoagulants  Academic Article
• Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group  Academic Article
• Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale  Academic Article
• Perioperative management of patients who are receiving a novel oral anticoagulant  Academic Article
• Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial  Academic Article
• Periprocedural Management of Oral Anticoagulation  Academic Article
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Academic Article
• Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients  Academic Article
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Academic Article
• Phase I trial of lonidamine with whole body hyperthermia in advanced cancer.  Academic Article
• Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.  Academic Article
• Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose  Academic Article
• Platelet count or bleeding as the outcome in ITP trials?  Academic Article
• Positioning new treatments in the management of immune thrombocytopenia  Academic Article
• Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation  Academic Article
• Potential of new anticoagulants in patients with cancer  Academic Article
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Academic Article
• Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease.  Academic Article
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Academic Article
• Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study  Academic Article
• Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study  Academic Article
• Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis  Academic Article
• Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis  Academic Article
• Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment  Academic Article
• Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial  Academic Article
• Reducing the risk of recurrent stroke in patients with AF  Academic Article
• Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation  Academic Article
• Response.  Academic Article
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Academic Article
• Review: In renal impairment, apixaban reduces, or does not increase, bleeding compared with other anticoagulants  Academic Article
• Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial  Academic Article
• Riociguat for the treatment of pulmonary hypertension  Academic Article
• Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension  Academic Article
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Academic Article
• Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants  Academic Article
• Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib  Academic Article
• Rivaroxaban for the prevention and treatment of venous thromboembolism  Academic Article
• Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma  Academic Article
• Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available  Academic Article
• Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study  Academic Article
• Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation  Academic Article
• Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment  Academic Article
• Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature  Academic Article
• Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial  Academic Article
• Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease  Academic Article
• Stroke prevention in atrial fibrillation: Closing the gap  Academic Article
• Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance  Academic Article
• Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists  Academic Article
• Synergistic effect of purine derivatives on the toxicity of pyrazofurin and 6-azauridine towards cultured mammalian cells  Academic Article
• Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial  Academic Article
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations  Academic Article
• The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale  Academic Article
• The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial  Academic Article
• The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB₁receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use  Academic Article
• The gut microbiome restores intrinsic and extrinsic nerve function in germ‐free mice accompanied by changes in calbindin  Academic Article
• The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis  Academic Article
• The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study  Academic Article
• The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis  Academic Article
• The top 4 advances in antithrombotic care in the last year  Academic Article
• Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline  Academic Article
• Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia  Academic Article
• Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia  Academic Article
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Academic Article
• Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014  Academic Article
• Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma  Academic Article
• Use of a competitive inhibitor in a kinetic enzymatic method for measuring ethanol in serum.  Academic Article
• Venous thromboembolism management: where do novel anticoagulants fit?  Academic Article
• Well-managed warfarin is superior to NOACs Response  Academic Article